West Pharmaceutical Services Inc
WST: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$476.00 | Xjqx | Jqbmzrgqd |
West Pharmaceutical Earnings: Maintaining Valuation as Base Business Sees Solid Growth and Margins
West Pharmaceutical saw a 2.3% net sales decline in the second quarter, with a sharper decline in adjusted diluted EPS, but management slightly raised expectations for both measures for the full year. Our earnings forecast was already above the high end of prior guidance, so we are maintaining our $290 fair value estimate.